Vulvar Lichen Planus: Symptoms, Causes & Treatment

Comprehensive Clinical Guide: Vulvar Lichen Planus (VLP)

Vulvar Lichen Planus (VLP) represents a chronic, inflammatory, T-cell-mediated dermatosis that specifically targets the mucocutaneous tissues of the vulva. As a subset of the broader Lichen Planus spectrum, VLP is frequently underdiagnosed or misidentified as chronic candidiasis, lichen sclerosus, or contact dermatitis. Given its potential for progressive tissue destruction, scarring, and profound impact on quality of life, a nuanced clinical understanding is mandatory for gynecologists, dermatologists, and primary care practitioners.

1. Clinical Definition and Etiology

Definition

Vulvar Lichen Planus is a chronic autoimmune condition characterized by the destruction of the basal layer of the epidermis/epithelium. It is classified under the "Lichenoid Tissue Reaction" (LTR) pattern and typically presents in three clinical forms: erosive, papulosquamous, and hypertrophic.

Etiology and Pathogenesis

The precise trigger for VLP remains idiopathic in the majority of cases; however, current medical consensus points toward a cell-mediated immunological response.

T-Cell Mediation: The primary mechanism involves the activation of CD8+ cytotoxic T-lymphocytes targeting basal keratinocytes.
Cytokine Cascade: An upregulation of pro-inflammatory cytokines, specifically Interferon-gamma (IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α), promotes epithelial apoptosis.
Genetic Predisposition: Associations with specific HLA subtypes (e.g., HLA-DR1) suggest a genetic susceptibility to autoimmune reactions in mucosal tissues.
Drug-Induced Lichenoid Eruptions: While rarer on the vulva, certain medications (ACE inhibitors, NSAIDs, gold salts, and beta-blockers) can trigger lichenoid reactions that mimic VLP.

2. Pathophysiology and Clinical Staging

The pathophysiology of VLP follows a predictable progression of chronic inflammation leading to architectural remodeling.

Mechanism of Tissue Damage

Interface Dermatitis: T-lymphocytes infiltrate the dermo-epidermal junction.
Basal Layer Vacuolization: Damage to the basement membrane zone (BMZ) leads to "liquefaction degeneration."
Colloid Body Formation: Apoptotic keratinocytes form Civatte bodies.
Fibrosis: Chronic inflammation triggers fibroblast activity, leading to scarring (synechiae).

Clinical Variants (Classification)

Variant	Clinical Presentation
Erosive (E-VLP)	Most common; bright red, painful, weeping erosions with white striae (Wickham striae).
Papulosquamous	Violaceous, polygonal papules; often asymptomatic or mildly pruritic.
Hypertrophic	Thickened, warty, or lichenified plaques; high risk of misdiagnosis as HPV.

3. Clinical Presentation and Diagnostic Criteria

Standard Presentation

Patients typically present with a triad of symptoms: dyspareunia (painful intercourse), burning, and pruritus.

Wickham Striae: The hallmark clinical sign. These are white, lacy, reticulated lines found on the mucosal surface, often surrounding erosions.
Architectural Loss: In advanced cases, the vulva undergoes "resorption." This includes the loss of the labia minora, narrowing of the introitus, and clitoral burial (phimosis of the clitoral hood).
Multisite Involvement: VLP is often part of the "Vulvovaginal-Gingival Syndrome" (VVG), where patients also exhibit desquamative gingivitis and vaginal erosions.

Differential Diagnosis

The clinician must differentiate VLP from:
1. Lichen Sclerosus (LS): LS causes thinning/parchment skin; VLP causes erosive, angry red inflammation.
2. Candidiasis: Often excluded via KOH prep or fungal culture.
3. Pemphigus Vulgaris: Requires direct immunofluorescence (DIF) to distinguish.
4. Fixed Drug Eruption: History of recent medication changes.

Diagnostic Testing

Punch Biopsy: The Gold Standard. A 3-4mm punch biopsy is taken from the edge of an erosion or a plaque.
Direct Immunofluorescence (DIF): Essential to rule out autoimmune blistering diseases. Shows shaggy fibrinogen deposits along the BMZ.
Vaginal pH/Wet Mount: To rule out concurrent infections (BV, Yeast, Trichomoniasis) which often exacerbate symptoms.

4. Risks, Side Effects, and Long-Term Prognosis

Prognosis

VLP is a lifelong condition with a relapsing-remitting course. While there is no "cure," it is highly manageable.

Malignant Potential: Erosive VLP carries a small but significant risk (approx. 1-3%) of transformation into Squamous Cell Carcinoma (SCC). Regular surveillance is mandatory.
Functional Impact: Untreated VLP can lead to complete obliteration of the vaginal introitus, making sexual intercourse impossible and pelvic exams extremely difficult.

Contraindications and Risks of Treatment

High-Potency Steroids: Prolonged use can lead to skin atrophy, telangiectasia, and secondary striae.
Systemic Immunosuppressants: Risks include hepatotoxicity (methotrexate), renal monitoring (cyclosporine), and opportunistic infection.

5. Management and Therapeutic Strategy

Management is tiered based on the severity of symptoms and the extent of erosions.

First-Line Therapy

Ultra-Potent Topical Corticosteroids: Clobetasol propionate 0.05% ointment. Application: Twice daily for 2-4 weeks, then taper to maintenance (twice weekly).
Topical Calcineurin Inhibitors: Tacrolimus 0.1% ointment. Useful for maintenance to avoid steroid-induced atrophy.

Second-Line / Refractory Therapy

Intralesional Steroids: Triamcinolone acetonide injections for hypertrophic plaques.
Systemic Therapies: Hydroxychloroquine, Methotrexate, or Mycophenolate mofetil for recalcitrant cases.
Surgical Intervention: Perineoplasty or vestibulectomy is reserved strictly for patients with severe scarring/stenosis who have achieved disease quiescence.

6. Massive FAQ Section

Q1: Is Vulvar Lichen Planus contagious?

No. VLP is an autoimmune, inflammatory condition. It is not sexually transmitted, nor is it caused by poor hygiene.

Q2: How is VLP different from Lichen Sclerosus?

While both are autoimmune, LS usually presents with white, thin, "cigarette paper" skin and carries a higher risk of SCC. VLP presents with erosions, intense redness, and potential scarring of the vaginal canal.

Q3: Why does my mouth hurt if I have a vulvar condition?

This is known as the Vulvovaginal-Gingival (VVG) syndrome. It is a severe variant of VLP where the immune system attacks both oral and genital mucosa.

Q4: Will I ever be able to have sex again?

Yes, with appropriate management to control inflammation and restore tissue elasticity, many patients successfully resume sexual activity. In severe cases, dilator therapy is recommended.

Q5: Is a biopsy always necessary?

Yes. Because VLP can mimic other conditions—including pre-cancerous lesions—a biopsy is the only way to confirm the diagnosis and ensure the correct treatment plan is implemented.

Q6: Can diet cure VLP?

There is no evidence that diet cures VLP. However, some patients find that avoiding acidic foods (like citrus or tomatoes) reduces burning sensations during urination.

Q7: What is the risk of cancer?

The chronic inflammation associated with erosive VLP can lead to malignant transformation. Annual follow-up exams with a gynecologist or dermatologist are essential.

Q8: Can I use over-the-counter creams for the pain?

Avoid OTC creams containing benzocaine or "caine" derivatives, as they can cause contact dermatitis and worsen the inflammation of the already sensitive mucosa.

Q9: Does stress trigger flares?

Yes. As an autoimmune-mediated condition, many patients report that flares occur during periods of high physiological or psychological stress.

Q10: How long do I have to use the steroid ointment?

Treatment is usually tapered. You start with a "loading phase" to stop the inflammation and transition to a "maintenance phase" to prevent recurrence. Never stop cold turkey without consulting your specialist.

7. Clinical Summary Table: Treatment Overview

Medication Class	Example	Role
Ultra-Potent Steroid	Clobetasol Propionate	Induction of remission
Calcineurin Inhibitor	Tacrolimus 0.1%	Maintenance/Steroid-sparing
Systemic Agent	Methotrexate	Severe/Refractory disease
Adjunct Therapy	Sitz baths/Emollients	Symptom relief/Barrier protection

8. Conclusion for Practitioners

The management of Vulvar Lichen Planus requires a multidisciplinary approach. Early intervention is the most critical factor in preventing permanent anatomical destruction. Practitioners should maintain a low threshold for biopsy, prioritize patient education regarding the chronic nature of the disease, and ensure long-term surveillance for potential malignant transformation. By adhering to a structured steroid-tapering regimen and utilizing topical calcineurin inhibitors for maintenance, clinicians can significantly improve the quality of life for patients suffering from this debilitating condition.

Disclaimer: This guide is intended for informational and educational purposes for healthcare professionals. It does not replace professional medical judgment. Always refer to current clinical guidelines and institutional protocols when treating individual patients.